Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of recombinant botulinum toxin type A injection for primary axillary hyperhidrosis
CTR20263569Phase 2Active
- Sponsor
- Ruoyi Biotech
- Start
- Oct 2026
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of JHM03 in essential axillary hyperhidrosis, sponsored by Ruoyi Biotech. Started Oct 2026; status: active.
02
Drugs
JHM03
03
Conditions
essential axillary hyperhidrosis
Beyond the preview
Go deeper on CTR20263569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263569.